Skip to main content

An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304

Trial Status: Enrolling by Invitation

This is a multi-center, open-label, study to evaluate the safety and efficacy of ublituximab (TG-1101) in combination with TGR-1202 for patients who have progressed on treatment arms previously enrolled in Protocol UTX-TGR-304

Inclusion Criteria

  • Prior treatment in clinical trial UTX-TGR-304
  • Eastern Cooperative Oncology Group (ECOG) score of 0 to 2

Exclusion Criteria

  • Patients refractory to ublituximab + TGR-1202
  • Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's transformation)

California

Duarte
City of Hope Comprehensive Cancer Center
Status: ACTIVE
Contact: Tanya Siddiqi
Phone: 800-826-4673

Connecticut

New Haven
Yale University
Status: ACTIVE
Contact: Laura Leary
Phone: 203-800-1969

Kansas

Kansas City
University of Kansas Cancer Center
Status: ACTIVE
Overland Park
University of Kansas Cancer Center-Overland Park
Status: ACTIVE
Westwood
University of Kansas Hospital-Westwood Cancer Center
Status: ACTIVE

Missouri

Kansas City
The University of Kansas Cancer Center-South
Status: ACTIVE
University of Kansas Cancer Center - North
Status: ACTIVE

New Hampshire

Lebanon
Dartmouth Hitchcock Medical Center
Status: ACTIVE
Contact: Frederick Lansigan
Phone: 800-639-6918

North Carolina

Durham
Duke University Medical Center
Status: ACTIVE
Contact: Danielle M Brander
Phone: 888-275-3853

Oregon

Portland
OHSU Knight Cancer Institute
Status: CLOSED_TO_ACCRUAL

Pennsylvania

Philadelphia
University of Pennsylvania / Abramson Cancer Center
Status: ACTIVE

Virginia

Charlottesville
University of Virginia Cancer Center
Status: ACTIVE

Washington

Seattle
Fred Hutch / University of Washington Cancer Consortium
Status: ACTIVE

Trial Phase Phase II

Trial Type Treatment

Lead Organization
TG Therapeutics Inc

  • Primary ID UTX-TGR-204
  • Secondary IDs NCI-2016-01255
  • Clinicaltrials.gov ID NCT02656303